Vimarsana
Biggest News Aggregation in the World

Page 40 - Wave Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Wave Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Wave Life Sciences Today - Breaking & Trending Today

DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed - Vimarsana News

DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed

DGAP-News: BB Biotech AG / Key word(s): Annual Results/Dividend BB BIOTECH AG: 2021 was a difficult year for biotech equity markets -...

Roche revives a closely watched Huntington's disease drug - Vimarsana News

Roche revives a closely watched Huntington's disease drug

BioPharma

A high-profile gene therapy biotech takes aim at Huntington's - Vimarsana News

A high-profile gene therapy biotech takes aim at Huntington's

BioPharma

Investegate |BB BIOTECH AG Announcements | BB BIOTECH AG: BB Biotech: Gains realized following COVID-19 vaccine booster update enable increases in oncology and CNS - Vimarsana News

Investegate |BB BIOTECH AG Announcements | BB BIOTECH AG: BB Biotech: Gains realized following COVID-19 vaccine booster update enable increases in oncology and CNS

Investegate announcements from BB BIOTECH AG, BB Biotech: Gains realized following COVID-19 vaccine booster update enable increases in oncology and CNS

Fierce Pharma Asia—Hansoh's siRNA deals; J&J preps for Legend's CAR-T launch; Brii's COVID antibodies - Vimarsana News

Fierce Pharma Asia—Hansoh's siRNA deals; J&J preps for Legend's CAR-T launch; Brii's COVID antibodies

China's Hansoh Pharma inked two siRNA partnerships. Johnson & Johnson intends to roll out a tailored patient support program for Legend Biotech's upcoming CAR-T therapy. Brii Biosciences' COVID-19 antibody combo could be a blockbuster opportunity, one analyst said. And more.